Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The role of tumor-infiltrating immune cells in the early metastatic invasion of colorectal cancer is unknown. METHODS: We studied pathological signs of early metastatic invasion (venous emboli and lymphatic and perineural invasion) in 959 specimens of resected colorectal cancer. The local immune response within the tumor was studied by flow cytometry (39 tumors), low-density-array real-time polymerase-chain-reaction assay (75 tumors), and tissue microarrays (415 tumors). RESULTS: Univariate analysis showed significant differences in disease-free and overall survival according to the presence or absence of histologic signs of early metastatic invasion (P<0.001). Multivariate Cox analysis showed that an early conventional pathological tumor-node-metastasis stage (P<0.001) and the absence of early metastatic invasion (P=0.04) were independently associated with increased survival. As compared with tumors with signs of early metastatic invasion, tumors without such signs had increased infiltrates of immune cells and increased levels of messenger RNA (mRNA) for products of type 1 helper effector T cells (CD8, T-BET [T-box transcription factor 21], interferon regulatory factor 1, interferon-gamma, granulysin, and granzyme B) but not increased levels of inflammatory mediators or immunosuppressive molecules. The two types of tumors had significant differences in the levels of expression of 65 combinations of T-cell markers, and hierarchical clustering showed that markers of T-cell migration, activation, and differentiation were increased in tumors without signs of early metastatic invasion. The latter type of tumors also had increased numbers of CD8+ T cells, ranging from early memory (CD45RO+CCR7-CD28+CD27+) to effector memory (CD45RO+CCR7-CD28-CD27-) T cells. The presence of high levels of infiltrating memory CD45RO+ cells, evaluated immunohistochemically, correlated with the absence of signs of early metastatic invasion, a less advanced pathological stage, and increased survival. CONCLUSIONS: Signs of an immune response within colorectal cancers are associated with the absence of pathological evidence of early metastatic invasion and with prolonged survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Examination of the lymphocytes that correlated with such beneficial outcomes has repeatedly implicated effector and memory CD8 + T cell and NK cell populations (136-141).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [136]
Citations
Cites
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
TNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
TNM Classification of Malignant Tumours
(2003) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471463752 · Cited by 3,946
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067
Research works printed but not linked: 2
- 10.1002/(sici)1097-0142(20000401)88:7<1739::aid-cncr30>3.0.co;2-t · DOI · Paper page
- 10.1002/(sici)1097-0215(19990621)84:3<326::aid-ijc22>3.0.co;2-k · DOI · Paper page
Cited by
Items 901–1,000 of 1,001
Lim, Y., Choi, S., Oh, H. J., Kim, C., Song, S., Kim, S., Song, H., Park, S., Kim, J. W., Kim, J. H., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00470-0 · Cited by 39
“…fi ltrating lymphocytes (TIL) in the tumor microenvironment, which can re fl ect the host ’ s immune response to the tumor, have long been recognized as a biomarker that can be related to cancer prognosis 4 – 6 , and have recently been highlighted as a practical prognostic biomarker for colon cancer.”
Jou, E., Chaudhury, N., & Nasim, F. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00212 · Cited by 43
Regulatory T cells, dendritic cells and neutrophils in patients with renal cell carcinoma
Minárik, I., Lašťovička, J., Budínský, V., Kayserová, J., Špíšek, R., Jarolím, L., Fialová, A., Babjuk, M., & Bartůňková, J. (2013) · Immunology Letters · doi:10.1016/j.imlet.2013.05.010 · Cited by 33
The potential role of immunotherapy to treat colorectal cancer
Amin, M. A., & Lockhart, A. C. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.985376 · Cited by 37
“Similarly, the presence of CD8 T cells within the CRC tumors was associated with prolonged survival and also highlights the potential protective effects of intratumoral CD8 cells [46].”
BackgroundTrial Watch: Adoptive cell transfer for oncological indications
Aranda, F., Buqué, A., Bloy, N., Castoldi, F., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1046673 · Cited by 35
“Elevated amounts of natural tumor-infiltrating lymphocytes (TILs) have been correlated with improved disease outcome in cohorts of patients affected by various neoplasms.(18-23) Thus, TILs would represent a convenient source of potentially tumorreactive cells for ACT-based immunotherapy.”
BackgroundSelf-citationAltan, M., Haberal, H. B., Akdoğan, B., & Özen, H. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1150-x · Cited by 34
Tertiary Lymphoid Structures in Colorectal Cancers and Their Prognostic Value
Трајковски, Ѓ., Ognjenovic, L., Karadžov, Z., Jota, G., Hadzi-Manchev, D., Костовски, О., Volcevski, G., Trajkovska, V., Nikolova, D., Spasevska, L., et al. (2018) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2018.341 · Cited by 35
“There are evidences that high amount of tumour-infiltrating cells are more common in CRC with lower stage, in tumours with lower T status-local tumour growth, without nodal involvement and metastases and that CRC progression is influenced by inter-reaction between cancer cells and tumour microenvironment belonging to…”
BackgroundZhu, Q., Wu, Y., Yang, M., Wang, Z., Zhang, H., Jiang, X., Chen, M., Jin, T., & Wang, T. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23098 · Cited by 31
“The cancer immunoediting theory suggests that the immune system overlooks some tumor cells, which therefore escape the fate of being cleared from the body.(32) This indicates that IRX5 may be involved in the mechanism of immune escape.”
Huang, K. C., Chiang, S., Yang, P.-C., Ke, T., Chen, T.-W., Hu, C.-H., Huang, Y., Chang, H.-Y., Chen, W. T., & Chao, K. S. C. (2021) · Cancers · doi:10.3390/cancers13061218 · Cited by 34
Du, T., Gao, Q., Zhao, Y., Gao, J., Li, J., Wang, L., Li, P., Wang, Y., Du, L., & Wang, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.651796 · Cited by 36
“Furthermore, a recent study has proved that the expression of GZMB at the mRNA level is lower in early metastatic CRC (45).”
BackgroundRapoport, B. L., Nayler, S., Mlecnik, B., Smit, T., Heyman, L., Bouquet, I., Martel, M., Galon, J., Benn, C.-A., & Anderson, R. (2022) · Cancers · doi:10.3390/cancers14102525 · Cited by 33
“examined the role of tumor-infiltrating immune cells in patients with an early metastatic invasion of colorectal cancer; these investigations revealed that the presence of a high-density of infiltrating memory and effector memory T cells (CD45RO+) was associated with a lower incidence of lymphovascular and perineural…”
BackgroundSelf-citationImmune reaction and colorectal cancer: Friends or foes?
Formica, V., Cereda, V., Nardecchia, A., Tesauro, M., & Roselli, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i35.12407 · Cited by 36
Antibody-Based Therapy in Colorectal Cancer
Noguchi, T., Ritter, G., & Nishikawa, H. (2013) · Immunotherapy · doi:10.2217/imt.13.35 · Cited by 35
The stable traits of melanoma genetics: an alternate approach to target discovery
Spivey, T., Giorgi, V. D., Zhao, Y., Bedognetti, D., Pós, Z., Liu, Q., Tomei, S., Ascierto, M. L., Uccellini, L., Reinboth, J., et al. (2012) · BMC Genomics · doi:10.1186/1471-2164-13-156 · Cited by 35
“Finally, TARA’s class A metastases displayed a classic Th17 phenotype while class B a Th1; this finding is clinically relevant as the two immune phenotypes have distinct prognostic weight in cancer with the former being associated with poor prognosis [22] and the latter with good prognosis and likelihood to respond to…”
BackgroundSportès, C., & Hakim, F. T. (2009) · Springer eBooks · doi:10.1007/978-1-4020-9063-9_55 · Cited by 35
Barlev, E., Zelig, U., Bar, O., et al. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-015-1095-7 · Cited by 33
“there is evidence of a correlation between prognosis and levels of FOXP3? T regulatory cells and effector memory T cells in the microenvironment [26, 27].”
BackgroundMismatch repair gene defects in sporadic colorectal cancer enhance immune surveillance
Scarpa, M., Ruffolo, C., Canal, F., Scarpa, M., Basato, S., Erroi, F., Fiorot, A., Dallagnese, L., Pozza, A., Porzionato, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6179 · Cited by 39
“Moreover, Galon et al observed in 2006 a better survival in stage II CRC with an adequate TIL infiltration constituted mainly by Th1 and CD8+ T cells [19].”
BackgroundThe changes of Th17 cells and the related cytokines in the progression of human colorectal cancers
Wang, J., Xu, K., Wu, J., Luo, C., Li, Y., Wu, X., Gao, H.-F., Feng, G., & Yuan, B. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-418 · Cited by 37
“In addition, subtyping of immune cells within tumor tissues may be more effective in evaluating disease status than genetic changes [9-11].”
BackgroundColorectal Cancer Microenvironment: Among Nutrition, Gut Microbiota, Inflammation and Epigenetics
Garagnani, P., Pirazzini, C., & Franceschi, C. (2012) · Current Pharmaceutical Design · doi:10.2174/1381612811306040765 · Cited by 40
“Particular attention was dedicated to T cells’ population and it was reported that Treg can both promote or inhibit tumor progression through the immune response [105-107].”
BackgroundTumour budding in rectal cancer. A comprehensive review
Lino-Silva, L. S., Salcedo‐Hernández, R. A., & Gamboa‐Domínguez, A. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.77043 · Cited by 39
Penter, L., Dietze, K., Ritter, J. M., Cobo, M. F. L., Garmshausen, J., Aigner, F., Bullinger, L., Hackstein, H., Wienzek‐Lischka, S., Blankenstein, T. J. F., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1586409 · Cited by 33
Assessment of tumor-associated immune cells in laryngeal squamous cell carcinoma
Zhou, L., Li, Y., Gao, W., Huangfu, H., Wen, S., Zhang, C., Zhao, Q., Dong, Z., Qu, C., Li, G., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02936-w · Cited by 38
Fassan, M., Cavallin, F., Guzzardo, V., Kotsafti, A., Scarpa, M., Cagol, M., Chiarion‐Sileni, V., Saadeh, L. M., Alfieri, R., Castagliuolo, I., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2359 · Cited by 33
Assessment of the risk of permanent stoma after low anterior resection in rectal cancer patients
Zeman, M., Czarnecki, M., Chmielarz, A., Idasiak, A., Grajek, M., & Czarniecka, A. (2020) · World Journal of Surgical Oncology · doi:10.1186/s12957-020-01979-5 · Cited by 34
Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer
Ware, M. B., El‐Rayes, B. F., & Lesinski, G. B. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001100 · Cited by 34
“8 13–16 This observation parallels immune suppressive features of other tumors, including prostate and breast cancers.”
BackgroundImmunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
Zhong, C. F., Li, Y., Yang, J., Jin, S., Chen, G., Li, D., Fan, X., & Lin, H. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.589680 · Cited by 37
Multi-Omics Analysis Reveals Intratumor Microbes as Immunomodulators in Colorectal Cancer
Liu, Z., Zhang, X., Zhang, H., Zhang, H., Yi, Z., Zhang, Q., Liu, Q., & Liu, X. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.05038-22 · Cited by 36
“ing lymphocytes is associated with a better prognosis in advanced CRC (14).”
BackgroundHalama, N., Zoernig, I., Spille, A., Michel, S., Kloor, M., Grauling-Halama, S., Westphal, K., Schirmacher, P., Jäger, D., & Grabe, N. (2010) · PubMed · Cited by 30
Serum granulysin level as a novel prognostic marker in patients with gastric carcinoma
Saigusa, S., Ichikura, T., Tsujimoto, H., et al. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04796.x · Cited by 32
Invariant natural killer T cells and immunotherapy of cancer
Molling, J. W., Moreno, M., van der Vliet, H. J., van den Eertwegh, A. J. M., Scheper, R. J., Blomberg, B. M. E. V., & Bontkes, H. J. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.07.025 · Cited by 35
Roselli, M., Formica, V., Cereda, V., Jochéms, C., Richards, J., Grenga, I., Orlandi, A., Ferroni, P., Guadagni, F., & Schlom, J. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1188243 · Cited by 33
d’Engremont, C., Vernerey, D., Pointet, A., Simone, G., Fein, F., Heyd, B., Koch, S., Vuitton, L., Kim, S. C. H., Jary, M., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2860-6 · Cited by 33
Self-citationKim, R. D., Coppola, D., Wang, E., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25163 · Cited by 32
“Previous reports suggested CD45RO expressing immune cell infiltration as an independent prognostic marker in gastrointestinal cancer including colorectal and gastric cancer [8, 9].”
BackgroundPerales‐Puchalt, A., Wojtak, K., Duperret, E. K., Yang, X., Slager, A. M., Yan, J., Muthumani, K., Montaner, L. J., & Weiner, D. B. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.11.014 · Cited by 32
The appearance of Tregs in cancer nest is a promising independent risk factor in colon cancer
Xu, W., Liu, H., Song, J., Fu, H.-X., Qiu, L., Zhang, B.-F., Li, H.-Z., Bai, J., & Zheng, J.-N. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1500-7 · Cited by 31
High endothelial venule-like vessels and lymphocyte recruitment in testicular seminoma
Sakai, Y., Hoshino, H., Kitazawa, R., & Kobayashi, M. (2014) · Andrology · doi:10.1111/j.2047-2927.2014.00192.x · Cited by 31
McCann, K. J., Mander, A., Cazaly, A. M., Chudley, L., Stasakova, J., Thirdborough, S. M., King, A., Lloyd-Evans, P., Buxton, E., Edwards, C., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2507 · Cited by 31
“If immunologic visibility of the tumor is reflected in the presence of tumor-infiltrating lymphocytes and links to survival (9, 10), activating preexisting antigen-specific T-cell responses could be an effective approach to improving clinical outcomes.”
BackgroundThe clinical implications of immunogenomics in colorectal cancer: A path for precision medicine
Riley, J. M., Cross, A. W., Paulos, C. M., Rubinstein, M. P., Wrangle, J. M., & Camp, E. R. (2018) · Cancer · doi:10.1002/cncr.31214 · Cited by 37
“Pioneering studies in CRC have strengthened the association between the tumor immune landscape and the clinical prognosis.(8,9,24,25) Galon et al(8,26) defined the immunoscore, a histology-based analysis of the cancer’s invasive margin or central location of memory and cytotoxic TILs based on CD3 and CD8 staining.”
BackgroundStrategy to targeting the immune resistance and novel therapy in colorectal cancer
Wang, G., Wang, J., Guan, R., Sun, Y., Shi, F., Zhang, J., Li, Z., Gao, J., & Fu, X. (2018) · Cancer Medicine · doi:10.1002/cam4.1386 · Cited by 35
Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy
Zhang, M., Yang, H. J., Hua, W., Zhong, L., Xu, Z., & Qian, Q. (2019) · Frontiers of Medicine · doi:10.1007/s11684-018-0678-0 · Cited by 38
The 100 top-cited studies in cancer immunotherapy
Zhang, Y., Quan, L., & Du, L. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1623234 · Cited by 32
“Effector memory T cells, early metastasis, and survival in colorectal cancer [40] New England Journal of Medicine Basic research 1125 2005 13 16371631”
BackgroundRos, S., Navas-Carrillo, D., Alonso-Romero, J. L., & Orenes‐Piñero, E. (2020) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2020.1729692 · Cited by 32
Ren, J., Yang, Y., Li, C., Xie, L., Hu, R., Qin, X., & Zhang, M. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2020.634634 · Cited by 37
Bonilla, W. V., Kirchhammer, N., Marx, A., Kallert, S. M., Krzyzaniak, M. A., Lu, M., Darbre, S., Schmidt, S., Raguz, J., Berka, U., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100209 · Cited by 31
Tang, Y., Jiang, M., Chen, A., Qu, W., Han, X., Zuo, J., Xu, G., Song, Y., Chen, C., & Ke, X. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12189 · Cited by 33
“Among patients, the tumor microenvironment can vary dramatically and lead to different therapeutic outcomes and prognoses due to the different compositions of immune cell subsets (5,6).”
BackgroundWu, Y., Wu, M., Ming, S., Zhan, X., Hu, S., Li, X., Yin, H., Cao, C., Liu, J., Li, J., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci137407 · Cited by 35
Mlecnik, B., Lugli, A., Bindea, G., Marliot, F., Bifulco, C. B., Lee, J. J., Zlobec, I., Rau, T. T., Berger, M. D., Nagtegaal, I. D., et al. (2023) · Cancers · doi:10.3390/cancers15020418 · Cited by 42
“A very high-risk category was defined based on T4 primary tumors and VELIPI+, as well as an additional group with T4N0 tumors only.”
BackgroundInfluentialSelf-citationSeo, G. S., Jiang, W., Chi, J. H., Jin, H., Park, W.-C., Sohn, D. H., Park, P., & Lee, S. H. (2015) · Oncotarget · doi:10.18632/oncotarget.4075 · Cited by 37
“High densities of T cells with a Th1 and CD8+ T cell cytotoxic orientation or of mature dendritic cells are essential for antitumor immunity [20–22].”
BackgroundRecchia, F., Saggio, G., Cesta, A., Candeloro, G., Blasio, A. D., Amiconi, G., Lombardo, M., Nuzzo, A., Lalli, A., Alesse, E., et al. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0224-9 · Cited by 32
“The host immune response plays a key role in controlling metastatic spread, MRD, and survival in patients with colorectal cancers [ 26 ].”
BackgroundAdvances in understanding of colorectal liver metastasis and implications for the clinic
Page, A. J., Cosgrove, D. C., Herman, J. M., & Pawlik, T. M. (2014) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2014.940897 · Cited by 33
“Recently, there has been increased research in the relationship between hepatic immune surveillance and the prognosis of metastatic colorectal cancer [28].”
BackgroundImmune regulation and anti-cancer activity by lipid inflammatory mediators
Khadge, S., Sharp, J. G., McGuire, T. R., Thiele, G. M., Black, P. N., Dirusso, C., Cook, L. M., Klassen, L. W., & Talmadge, J. E. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.10.026 · Cited by 35
Schollbach, J., Kircher, S., Wiegering, A., Seyfried, F., Klein, I., Rosenwald, A., Germer, C., & Löb, S. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02306-y · Cited by 35
Stresses in the metastatic cascade: molecular mechanisms and therapeutic opportunities
Shen, M., & Kang, Y. (2020) · Genes & Development · doi:10.1101/gad.343251.120 · Cited by 34
“Cytotoxic T-cell infiltration is correlated with good metastasis-free survival in cancers (Zhang et al. 2003; Pagès et al. 2005), suggesting that these cells restrain metastasis.”
BackgroundAscierto, P. A., Maio, E. D., Bertuzzi, S., Palmieri, G., Halaban, R., Hendrix, M. J. C., Kashani-sabet, M., Ferrone, S., Wang, E., Cochran, A. J., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-32 · Cited by 32
“In fact, characterization of the tumor-infiltrating immune cells in large cohorts of human colorectal cancers by gene expression profiling and in situ immunohistochemical staining to evaluate the expression levels of genes related to inflammation, TH1 adaptive immunity, and immunosuppression suggested that TH1 adaptiv…”
BackgroundSelf-citationRossi, A., Belmonte, B., Carnevale, S., Liotti, A., Rosa, V. D., Jaillon, S., Piconese, S., & Tripodo, C. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.933113 · Cited by 37
ANTI-TUMOR IMMUNE RESPONSES INDUCED BY RADIOTHERAPY: A REVIEW
Yoshimoto, Y., Kono, K., & Suzuki, Y. (2015) · FUKUSHIMA JOURNAL OF MEDICAL SCIENCE · doi:10.5387/fms.2015-6 · Cited by 29
Anti-tumor activity of patient-derived NK cells after cell-based immunotherapy – a case report
Milani, V., Stangl, S., Issels, R. D., et al. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-50 · Cited by 30
“an up-regulation of inhibitory NK ligands such as HLA-E molecules [23,39].”
BackgroundMaturation of dendritic cells by pullulan promotes anti-cancer effect
Zhang, W., Yu, X., Kwak, M., Xu, L., Zhang, L., Yu, Q., & Jin, J. (2016) · Oncotarget · doi:10.18632/oncotarget.10183 · Cited by 31
Zhou, Y., Ji, Y. I., Wang, H., Hai, Z., & Zhou, H. (2018) · Technology in Cancer Research & Treatment · doi:10.1177/1533033818780091 · Cited by 33
“numbers of intratumoral cytotoxic (CD8þ) and memory T cells (CD45ROþ) have been shown to correlate with an aggressive phenotype reflected by tumor microinvasive status.(3) In particular, many studies indicate that a high density of tumorinfiltrating regulatory T (Treg) cells correlates with the outcome of CRC.”
BackgroundEvangelou, Z., Papoudou‐Bai, A., Karpathiou, G., Kourea, H. P., Kamina, S., GOUSSIA, A. C., Harissis, H., Peschos, D., & Batistatou, A. K. (2020) · In Vivo · doi:10.21873/invivo.11818 · Cited by 33
Mechanistic insights of adipocyte metabolism in regulating breast cancer progression
Zhang, F., & Liu, S. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104741 · Cited by 35
Li, Q., Zhang, D., He, W., Chen, T., Yan, Z., Gao, X., Chen, L., Zheng, X. W., Xu, B., Lu, B., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11828 · Cited by 32
Park, D., Airi, R., & Sherman, M. (2020) · BMJ Case Reports · doi:10.1136/bcr-2020-235293 · Cited by 33
Data Driven Mathematical Model of Colon Cancer Progression
Kirshtein, A., Akbarinejad, S., Hao, W., Le, T., Su, S., Aronow, R. A., & Shahriyari, L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123947 · Cited by 37
“However, it has been observed that a high proportion of CD8 + T cells, effector memory T cells and CD4 + T cells is correlated with longer survival in colorectal cancer [31–33].”
Curran, T., Sun, Z., Gerry, B., Findlay, V. J., Wallace, K., Li, Z., Paulos, C. M., Ford, M. E., Rubinstein, M. P., Chung, D., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3753 · Cited by 33
Neoplastic “Black Ops”: Cancer's subversive tactics in overcoming host defenses
Biragyn, A., & Longo, D. L. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.01.005 · Cited by 32
Luo, X., Ding, Q., Wang, M., Li, Z., Mao, K., Sun, B., Pan, Y., Wang, Z., Zang, Y. Q., & Chen, Y. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010149 · Cited by 31
“In certain human tumors, the presence of an effective immune response is associated with good prognosis [48,49].”
BackgroundChen, H., & Chan, Y. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00314 · Cited by 32
“HCMV and tumor-infiltrating T cells Using immunohistochemical staining, quantitative PCR, and large-scale flowcytometry, recent studies have demonstrated the critical role of localized adaptive immune reaction in the prognosis of cancer behavior and prognosis (39, 40).”
BackgroundRegulatory T Cells in Colorectal Cancer: From Biology to Prognostic Relevance
Mougiakakos, D. (2011) · Cancers · doi:10.3390/cancers3021708 · Cited by 34
“Other contributing molecules are heme-oxygenase 1 (HO-1), cyclooxygenase 2 (COX-2), H-Ferritin, IDO [58, 81-83] and of course defective APCs [58,80-82].”
BackgroundPhenotype molding of T cells in colorectal cancer by single‐cell analysis
Di, J., Liu, M., Fan, Y., Gao, P., Wang, Z., Jiang, B., & Su, X. (2020) · International Journal of Cancer · doi:10.1002/ijc.32856 · Cited by 37
“CD45RO+ T cells is negatively associated with tumor relapse and positively related to survival.(9) Tumor-infiltrating CD3+ T”
BackgroundHarless, W. W., & Qiu, Y. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.04.032 · Cited by 30
“[20] Pages F et al.”
BackgroundNeoadjuvant immunotherapy in mismatch-repair-proficient colon cancers
Tan, P. B., Verschoor, Y. L., van den Berg, J. G., Balduzzi, S., Kok, N. F. M., Ijsselsteijn, M. E., Moore, K., Jurdi, A. A., Tin, A., Kaptein, P., et al. (2025) · Nature · doi:10.1038/s41586-025-09679-4 · Cited by 42
Microenvironnement immunitaire et cancer: Intérêt de l’immunoscore pour prédire l’évolution clinique
Galon, J., Bindea, G., Mlecnik, B., Angell, H. K., Lagorce, C., Mușină, A.-M., Berger, A., & Pagès, F. (2014) · médecine/sciences · doi:10.1051/medsci/20143004020 · Cited by 39
Self-citationThe value of inflammatory parameters in the prognosis of malignant mesothelioma
Abakay, Ö., Tanrıkulu, A. Ç., Palanci, Y., et al. (2014) · Journal of International Medical Research · doi:10.1177/0300060513504163 · Cited by 29
Chang, X., Zang, X., & Xia, C.-Q. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.288 · Cited by 29
Luo, Z., Wang, J., Zhang, Z., Li, H., Huang, L. J., Qiao, Y., Wang, D., Huang, J., Guo, L., Liu, J., et al. (2017) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607117715439 · Cited by 33
Jansen, C. S., Prokhnevska, N., & Kissick, H. T. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.10.011 · Cited by 35
“This resulted in the creation of a scoring system—the “Immunoscore”—based on the density of infiltrating CD8+ and CD45RO+ T-cells at the tumor core (CT) and invasive margin (IM), with higher scores reflecting greater lymphocyte invasion (52).”
BackgroundT-memory cells against cancer: Remembering the enemy
Sarkar, I., Pati, S., Dutta, A., Basak, U., & Sa, G. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2019.03.002 · Cited by 30
Fang, S., Tao, X., Xiong, M., Zhou, X., Wang, Y., Haydu, L. E., Ross, M. I., Gershenwald, J. E., Prieto, V. G., Cormier, J. N., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.03.1158 · Cited by 31
“We focused primarily on the cytotoxic T-cell subset because these cells can directly kill tumor cells and because the presence of cytotoxic T cells at the tumor site predicts favorable outcomes across multiple cancers (Li et al., 2016; Pages et al., 2005; Sato et al., 2005; Schumacher et al., 2001).”
BackgroundArriga, R., Caratelli, S., Lanzilli, G., Ottaviani, A., Cenciarelli, C., Sconocchia, T., Spagnoli, G. C., Iezzi, G., Roselli, M., Lauro, D., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32618 · Cited by 28
Song, Y., Jin, D., Chen, J., Luo, Z., Chen, G., Yang, Y., & Liu, X. (2020) · Aging · doi:10.18632/aging.103369 · Cited by 34
“Through perturbing the molecular signal and activating the immune response, immune cells could suppress tumor recurrence, progression and metastasis [11, 12].”
BackgroundMetabolic regulation of T lymphocyte motility and migration
Vuononvirta, J., Marelli‐Berg, F. M., & Poobalasingam, T. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100888 · Cited by 33
Laghi, L., Negri, F., Gaiani, F., Cavalleri, T., Grizzi, F., Angelis, G. L. D., & Malesci, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249680 · Cited by 35
“While data from randomized clinical studies have recognized clear survival advantages of adjuvant chemotherapy in stage III colon cancer patients [68,70], adjuvant therapy may not add enough benefit for cancer that invades the muscularis propria but has no lymph node involvement (stage IIA), while adjuvant chemotherap…”
BackgroundYoshida, C., Kadota, K., Ikeda, T., Ibuki, E., Go, T., Haba, R., & Yokomise, H. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.06.009 · Cited by 33
Kang, T. G., Park, H. J., Moon, J., Lee, J. H., & Ha, S. (2021) · Immune Network · doi:10.4110/in.2021.21.e23 · Cited by 36
Role of apoptosis resistance in immune evasion and metastasis of colorectal cancer
Liu, K. (2010) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v2.i11.399 · Cited by 30
The in situ local immune response, tumour senescence and proliferation in colorectal cancer
Roxburgh, C. S. D., Richards, C. H., Macdonald, A. I., Powell, A. G. M. T., McGlynn, L. M., McMillan, D. C., Horgan, P. G., Edwards, J., & Shiels, P. G. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.556 · Cited by 31
“…|DOI:10.1038/bjc.2013.556 2207 characterise these immune reactions, most work focusing on T lymphocytes and their subsets (CD3þ , CD4þ , CD8þ , CD45ROþ and FOXP3þ ) and macrophages (CD68þ ; Naito et al, 1998; Pages et al, 2005; Galon et al, 2006; Roxburgh and McMillan, 2012).”
BackgroundInfluentialDäster, S., Eppenberger‐Castori, S., Hirt, C., Soysal, S. D., Delko, T., Nebiker, C. A., Weixler, B., Amicarella, F., Iezzi, G., Governa, V., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1050574 · Cited by 33
“In particular, CRC infiltration by CD8C T cells has repeatedly been shown to be associated with favorable clinical outcome.(8,10,15,16) On the other hand, the role of innate immune system has not been studied in comparable detail.”
BackgroundLaengle, J., Stift, J., Bilecz, Á., Wolf, B., Beer, A., Hegedűs, B., Stremitzer, S., Starlinger, P. P., Tamandl, D., Pils, D., et al. (2018) · Theranostics · doi:10.7150/thno.24699 · Cited by 30
“In primary CRC, the presence of tumor infiltrating T helper type 1 (Th1), cytotoxic T lymphocytes (CTLs) and memory T cells are associated with an improved disease-free survival (DFS) and overall survival (OS) [6-12].”
BackgroundHan, E., Choi, H. Y., Kwon, H. J., Chung, Y. R., Shin, H.-C., Kim, E., Suh, K. J., Kim, S. H., Kim, J. H., & Park, S. Y. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01932-4 · Cited by 34
“One study showed that upregulated mRNA expression of intratumoral GNLY and GZMB was associated with a favorable outcome in patients with colorectal cancer [44].”
Krpina, K., Babarović, E., Đorđević, G., Fučkar, Ž., & Jonjić, N. (2012) · Croatian Medical Journal · doi:10.3325/cmj.2012.53.598 · Cited by 28
Tumor-infiltrating T cells and PD-L1 expression in childhood malignant extracranial germ-cell tumors
Boldrini, R., Pasquale, M. D. D., Melaiu, O., Chierici, M., Jurman, G., Benedetti, M. C., Salfi, N. C. M., Castellano, A., Collini, P., Furlanello, C., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1542245 · Cited by 29
“High density of tumor-infiltrating cytotoxic CD8 T cells, CD45RO memory T cells and CD4 helper T cells has been associated with good prognosis in various cancers.(2,3) On the contrary, high density of forlhead box protein 3-positive (FOXP3) CD4 tumor-infiltrating T lymphocytes (TILs), namely regulatory T (Treg) cells,…”
BackgroundTurato, C., Scarpa, M., Kotsafti, A., Cappon, A., Quarta, S., Biasiolo, A., Cavallin, F., Trevellin, E., Guzzardo, V., Fassan, M., et al. (2019) · Cancer Science · doi:10.1111/cas.13986 · Cited by 29
Fan, X., Jin, J., Yan, L., Liu, L., Li, Q., & Xu, Y. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108551 · Cited by 30
Enhancing mucosal immunity by transient microbiota depletion
Becattini, S., Littmann, E. R., Seok, R., Amoretti, L. A., Fontana, E., Wright, R. J., Gjonbalaj, M., Leiner, I. M., Plitas, G., Hohl, T. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18248-4 · Cited by 28
Characterization of the melanoma brain metastatic niche in mice and humans
Amit, M., Laider‐Trejo, L., Shalom, V., Shabtay‐Orbach, A., Krelin, Y., & Gil, Z. (2013) · Cancer Medicine · doi:10.1002/cam4.45 · Cited by 30
Immunotherapy of Metastatic Colorectal Cancer: Prevailing Challenges and New Perspectives
Zumwalt, T. J., & Goel, A. (2015) · Current Colorectal Cancer Reports · doi:10.1007/s11888-015-0269-2 · Cited by 30
Prognostic biomarkers in colorectal cancer: where do we stand?
Sagaert, X. (2014) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-013-1532-z · Cited by 33
“tumor-infiltrating, CD8-positive lymphocytes per high power field) are associated with improved outcome [47–55].”
BackgroundChen, H., Dilip Chakravarty, K., Wang, J., et al. (2010) · International Journal of Colorectal Disease · doi:10.1007/s00384-010-1020-8 · Cited by 28
“low nodal harvest might have worse survival as they have a weaker immunological response to their cancers [30].”
BackgroundNF-κB Fans the Flames of Lung Carcinogenesis
Wong, K., Jacks, T., & Dranoff, G. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0042 · Cited by 28
Metadata
- Authors
- Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., Meatchi, T., Bruneval, P., Cugnenc, P.-H., Trajanoski, Z., Fridman, W.-H., & Galon, J.
- Affiliations
- Inserm (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Graz University of Technology (AT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-12-22
- Volume
- 353
- Issue
- 25
- Pages
- 2654-2666
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2096151993
- Semantic Scholar
- 608c79dfb95b1632f3cda7f427350880ee435e8a
- Cited by
- 2,135
- References
- 32
- Citations by year
- 2026: 27 · 2025: 57 · 2024: 66 · 2023: 118 · 2022: 117 · 2021: 141 · 2020: 130 · 2019: 123 · 2018: 123 · 2017: 136 · 2016: 135 · 2015: 145 · 2014: 115 · 2013: 135 · 2012: 108
- FWCI
- 27.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- colorectal cancer, effector memory T cells, tumor-infiltrating lymphocytes, CD8+ T cells, CD45RO+ memory T cells, T-cell markers, lymphatic invasion, perineural invasion, interferon-gamma, granzyme B, granulysin, IRF1, disease-free survival, overall survival, antitumor immunity
- MeSH terms
- Analysis of Variance, Embolism, Flow Cytometry, Humans, Lymphatic Metastasis, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasm Staging, RNA, Messenger, T-Lymphocytes, Colorectal Neoplasms, Gene Expression, Proportional Hazards Models, Survival Analysis, Polymerase Chain Reaction, Lymphocytes, Tumor-Infiltrating, Leukocyte Common Antigens, CD8-Positive T-Lymphocytes, Microarray Analysis, Protein Tyrosine Phosphatase, Non-Receptor Type 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.